

IPV-Inactivated Poliovirus Vaccine (IPV)

Vaccine Description	<ul style="list-style-type: none"> • Brand: IPOL® • Inactive virus (IPV) preferred; Live attenuated virus (OPV) is no longer distributed in US • Contains neomycin, streptomycin, polymyxin B, formaldehyde, calf serum proteins, and 2-phenoxyethanol; needle cover contains dry natural latex rubber (see package insert) • Also available as combined DTaP, Engerix-B® (HepB), and IPV (Pediatrix®); combined DTaP and IPV (Kinrix™); combined DTaP, Hib, and IPV (Pentacel®) 		
Dose & Route	<ul style="list-style-type: none"> • Dose: 0.5 mL • Route: SC or IM (Precaution: hemophilia, thrombocytopenia, and anticoagulation therapy) 		
Indications	<ul style="list-style-type: none"> • All infants and children 2 months of age and older 		
Administration Schedule	Dose	Age	Minimum Interval
	#1	2 months	
	#2	4 months	4 weeks
	#3	6 to 18 months	4 weeks
	#4	4 to 6 years	6 months
Contraindications	<ul style="list-style-type: none"> • Serious allergic reaction to prior dose or vaccine component • Moderate or severe acute illness 		
Special Considerations	<ul style="list-style-type: none"> • DO NOT restart series, no matter how long since previous dose • May give dose #1 as early as 6 weeks of age • The final dose in the IPV series should be administered at age 4 years or older regardless of the number of previous doses • If person previously given OPV, finish series with IPV • 4 doses of any combination of OPV or IPV by 4 to 6 years of age constitutes a complete series 		
VIS: http://www.cdc.gov/vaccines/pubs/vis/downloads/vis-IPV.pdf			